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Purpose: To investigate a possible association between prenatal SSRI exposure and 
childhood overweight at 7-years of age.  
Methods: Information on pregnancy exposures and prevalence of childhood overweight at 7-
years of age was obtained from the Danish National Birth Cohort. Overweight was classified 
as BMI>85th percentile, based on age and sex. Based on an a priori hypothesis, we conducted 
analyses stratified by child sex to examine sex-specific differences.  
Results: Of eligible pregnant women, 127 reported using a SSRI, 490 reported having a 
psychiatric illness but no psychotropic medication use, and 35 568 reported no psychiatric 
illness and no psychotropic medication use. In comparison to children of mothers with a 
psychiatric illness but no SSRI use during pregnancy, prenatal SSRI exposure overall was not 
associated with an increased risk of childhood overweight (aPR 1.12 [95% confidence 
interval: 0.71, 1.77]). However, when stratified according to child sex, an increased risk was 
observed among males (aPR 1.78 [1.01, 3.12]) but not females (aPR 0.86 [0.37, 1.99]).  In 
contrast, female children of mothers with a psychiatric illness but no SSRI use during 
pregnancy were more likely to be overweight than female children of unexposed mothers 
(aPR 1.45 [1.05, 2.02]). This association was not mirrored among males (aPR 1.06 [0.76, 
1.50]). 
Conclusions: We observed the potential for opposing sex-specific differences in the long-
term effects of prenatal exposure to SSRI use and/or maternal psychiatric illness on 
childhood overweight. Limitations of the present study suggest further research in this area 
may be warranted with larger sample sizes and longer follow-up. 




SSRI – selective serotonin reuptake inhibitor 
PR – prevalence ratio 
CI – confidence interval 
5-HT – serotonin 
5-HTT – serotonin transporter 





Antidepressant use during pregnancy has increased dramatically over the last 10-15 
years. In Denmark, antidepressant use has increased from 0.8% of pregnancies in 1996 to 
4.1% in 2009 [1]. This trend is echoed in other countries such as the United States, where use 
of selective serotonin reuptake inhibitors (SSRIs) in particular has increased from 1.5% of 
pregnancies in 1996 to 6.4% in 2005 [2].  
Long-term effects of prenatal SSRI exposure is an important area of concern given the 
key role serotonin (5-HT) plays as a neurotransmitter within the central nervous system, 
affecting neurogenesis, migration and differentiation of neurons in the fetal brain [3-5]. The 
importance of the serotonergic system in regulating food intake and body weight places 
particular interest in the potential long-term effects of prenatal SSRI exposure on child 
growth [6-8].  
Sex-specific alterations in the serotonergic system, as a result of disruption of 5-HT 
homeostasis during critical periods of fetal development, have been identified in animal 
studies [9-14].  When serotonergic tone is increased, as a result of SSRI exposure, a resultant 
increase in negative feedback signalling is possible, which may blunt the maturation of the 
serotonergic system [15]. This could lead to altered development of the serotonergic system 
in early fetal life, which impacts on serotonergic regulation of food intake and body weight in 
later life, ultimately influencing the risk of childhood overweight [16]. Supporting this 
hypothesis is evidence from animal studies demonstrating that disruption of 5-HT 
homeostasis in utero results in adult-onset obesity in males, but not females [12, 14].  
Data from human studies, however, remains scarce. Two studies demonstrated a 
reduction in weight gain between 1-6 months of age among infants exposed to SSRIs [17, 
18], the long-term consequences of which are unknown. In contrast, a recent study involving 
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174 children with prenatal exposure to either a SSRI (N=46), major depression without SSRI 
(N=31) or no SSRI and no depression (N=97) observed no differences in infant growth with 
respect to weight, length, or head circumference from birth through 12 months of age [19]. 
Limitations of these studies make it difficult to draw accurate conclusions regarding potential 
long-term risks. Furthermore, an additional challenge in examining evidence generated from 
animal and human studies lies in understanding the complex interplay between prenatal SSRI 
exposure and exposure to maternal psychiatric illness or stress during pregnancy [16]. This is 
an important consideration as exposure to maternal psychiatric illness or stress during 
pregnancy is associated with long-term adverse effects on the metabolic health of the 
offspring [16], including increased risk of childhood overweight [20].  
Given the paucity of evidence, we sought to clarify whether prenatal SSRI exposure is 
associated with childhood overweight at 7-years of age, while taking into consideration the 




This study involves data obtained from mother-child dyads participating in the Danish 
National Birth Cohort, an ongoing nationwide, follow-up study of pregnant women and their 
children [21]. Recruitment took place from 1996 to 2002, with 60% of invited pregnant 
women agreeing to participate in initial studies. A total of 101 042 pregnancies were 
included. At the time of providing consent, women were asked to report on medication use 
during early pregnancy in a self-administered questionnaire (at approx. 6-10 weeks of 
gestation). After providing consent, women were interviewed by telephone twice during 
pregnancy, at 17 and 32 weeks gestation, and twice after pregnancy, when their children were 
6 and 18 months old. The cohort has been described elsewhere [21]. As part of the overall 
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study objectives of the DNBC, a self-administered questionnaire completed by parents was 
used to follow-up children at age 7. 
 
Study population 
Women included in this study were those who signed the original consent form and 
completed both prenatal interviews (N=80,669). We excluded women who took psychotropic 
medications other than SSRIs during pregnancy (i.e. anxiolytics (N=492), antipsychotics 
(N=45), antiepileptics (N=271)) or other antidepressants (N=64). Of the remaining women 
(N=79,797), we restricted the analysis to those who participated in postnatal interviews when 
their child was 6 months and 7-years of age (N=38,693). We further excluded dyads where 
child height and weight measurements were not recorded (N=2 370) or were outside of 
biologically plausible values (N=82), based on predefined criteria. In addition, we excluded 
dyads in which the child’s age at follow-up was less than 5 years (N=56), leaving a final 
study population of 36,185 mother-child dyads. This represented a loss to follow-up of 55%. 
 
Exposure variables 
SSRI use was defined as self-reported use of any drugs in World Health Organization-
defined Anatomic Therapeutic Chemical Classification System group N06AB during 
pregnancy [22]. Information on drug use was obtained from the initial consent form and both 
prenatal interviews and was coded either using predefined names or in a text string recorded 
by the interviewer and later coded for analysis by the investigators. Women were classified as 
exposed if they reported taking a SSRI at any stage during pregnancy.  
Presence of a psychiatric illness during pregnancy was identified based on maternal 
self-report, according to questions asked at the 2 prenatal interviews. In the first interview 
women were asked: (1) Have you ever suffered from a mental disorder or neurosis?; (2) Did 
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you see a medical doctor or psychologist for the disorder?; (3) What was the name of the 
disorder?; and (4) Have you experienced symptoms of the disorder during pregnancy? In the 




The primary outcome was childhood overweight at 7 years of age. The secondary 
outcome was Body Mass Index (BMI)-for-age z-scores. BMI (weight/(height(m)2) was 
calculated based on self-reported information from the parents on weight and height of the 
child. Women were asked to indicate who took the measurements (either the parents [67%] or 
the general practitioner/school nurse [33%]), with no difference in the source of the 
measurements according to exposure status (P=0.974). International cut-off scores were 
utilized to define overweight, i.e., a BMI at or exceeding the age- and sex-specific 85th 
percentile [23].  
 
Covariates 
Information on maternal age, parity, prenatal exposure to alcohol and smoking, and 
pre-pregnancy weight and height were obtained from the first prenatal interview. Parity was 
categorised as either primiparous (0) or multiparous (1-8 previous births). Smoking was 
categorised according to number of cigarettes smoked on average each day (none, 1-10 
cigarettes and >10 cigarettes per day). Maternal pre-pregnancy BMI was coded into three 
categories (<25; ≥25 to <30, and ≥30). The socioeconomic status score was defined as 
described by Bech et al. [24] by using data from the first prenatal interview. The score was 
based on the highest self-reported occupation of either the woman or her partner. Information 
on gestational weight gain and maternal postpartum distress was obtained from the first 
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postnatal interview. Gestational weight gain was categorised as low, normal, or high based on 
the U.S. Institute of Medicine (2009) recommendations for gestational weight gain for 
singleton pregnancies [25]. Information on breastfeeding was obtained from the second 
postnatal interview. Breastfeeding was categorised as breastfed <1 month (including no 
breastfeeding), 1-4 months and ≥4 months. Paternal BMI was coded in the same manner as 
maternal BMI. Maternal pre- and post- natal distress was assessed using 9 questions, which 
asked mothers about feelings of anxiety, depression and stress. Each question presented an 
item and was taken from two earlier validated questionnaires i.e., the Symptom Distress 
Checklist (SCL-90)[26] and the General Health Questionnaire (GHQ 60)[27]. Possible 
responses included; “no” = 0, “a little” =1 or “a lot” 2 (forming a 3-point Likert scale). The 
scores from the nine questions were summed together and treated as a continuous variable, 
the use of which has been previously validated [28].  
 
Statistical methods 
Statistical analyses were performed using Stata 11.1 (Stata, College Station, TX, 
USA). Characteristics between groups were compared using an unpaired t test, Wilcoxon 
rank-sum test, or Fisher’s exact test where appropriate. Rates of overweight were compared 
using a generalised linear model (Poisson distribution) with cluster-robust standard errors, 
yielding prevalence ratios (PRs) for the effect estimate and 95% confidence intervals (CIs). In 
a secondary analysis we examined differences in BMI-z scores between the groups using 
multiple linear regression analysis. Statistical significance was defined as a 2-sided P value of 
0.05.  
We included two adjusted models. The first included smoking status, pre-pregnancy 
maternal BMI, employment status, prenatal distress and paternal BMI, while the second 
included covariates in the first model and neonatal birth weight, weight gain during 
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pregnancy, breastfeeding and maternal postnatal distress score. In accordance with previous 
evidence highlighting the potential for sex-specific differences [17], based on an a priori 
hypothesis analyses were further stratified according to child sex. An interaction term 
between child sex and prenatal SSRI exposure was included in the linear and logistic 
regression analyses, but no statistical interactions were observed.  The sample size did not 
allow for stratification according to individual SSRI type or timing of exposure. 
To evaluate bias due to loss to follow-up, we used logistic regression (complete data 
vs. lost to follow-up as outcome) to determine weights for each individual using the inverse 
probability of response [29]. Complete follow-up data was predicted based on exposure to 
SSRIs or psychiatric illness during pregnancy, maternal age, parity, neonatal birth weight, 
maternal BMI, prenatal distress, smoking status and socioeconomic status. The individual 
weighting factor for these covariates (their inverse probability) was used as a sample 
weighting adjustment in subsequent analyses.  
Ethics Statement 
The Danish National Committee on Biomedical Research Ethics approves the 
establishment and the data collection of the DNBC. Written informed consent was obtained 
from each of the participants at the time of enrolment and mothers are able to withdraw at 
any time. This study was approved by the Danish Data Protection Agency, the Institutional 




Of the mother-child-dyads with follow-up data on weight and height (N=36 185), 127 
(0.4%) mothers reported taking a SSRI during pregnancy, 490 (1.4%) mothers reported 
having a psychiatric illness but no use of psychotropic medication and 35 568 (98.3%) 
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mothers did not report taking psychotropic medications or having a psychiatric illness during 
pregnancy (Table 1).   
A number of significant differences were apparent between women taking SSRIs and 
unexposed women (Table 1), with women taking SSRIs more likely to be of lower 
socioeconomic status, smoke during pregnancy and have higher prenatal and postnatal 
distress scores. In contrast, women taking SSRIs and women with a psychiatric illness but no 
SSRI use were comparable, except for the presence of a lower prenatal distress scores in 
those taking SSRIs. Sex and age of the children at follow-up did not differ significantly 
between groups (Table 1). 
After adjustment for confounders, no significant associations were observed between 
prenatal SSRI exposure and risk of overweight at 7-years of age (Table 2 and Table 3). 
When stratified according to child sex, however, male children with prenatal SSRI exposure 
were more likely to be overweight than male children of mothers with a psychiatric illness 
but no SSRI use (aPR 1.78 [1.01, 3.12]) and male children of unexposed mothers (aPR 1.54 
[1.01, 2.37]). In secondary analyses, no difference was observed in relation to BMI-z scores 
of male children with prenatal SSRI exposure compared to male children of mothers with a 
psychiatric illness but no SSRI use (0.30 [-0.06, 0.66]) or male children of unexposed 
mothers (0.11 [-0.17, 0.39]). 
While no increased risk of childhood overweight was observed amongst female 
children with prenatal SSRI exposure, female children of mothers with a psychiatric illness 
but no SSRI use during pregnancy were more likely to be overweight than female children of 
unexposed mothers (aPR 1.45 [1.05, 2.02]), and were more likely to have an elevated BMI-z 
score (0.21 [0.06, 0.36]).  
 
Discussion 
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We observed the potential for opposing sex-specific differences in the long-term 
effects of prenatal exposure to SSRI use and/or maternal psychiatric illness on childhood 
overweight. An increased risk of childhood overweight was observed among male, but not 
female, children following prenatal exposure to SSRIs. In contrast, an increased risk of 
childhood overweight was observed among female, but not male, children following prenatal 
exposure to maternal psychiatric illness without SSRI use.  
There is a convincing biologically plausible argument to expect different effect sizes 
according to child sex. Known sex variations in human brain development and function exist, 
including differences in the serotonergic system [30, 31]. For example, male 5-HTT knock-
out mice develop late-onset obesity [12, 14], while females are protected from this effect. 
While the mechanism underlying sex-specific differences is poorly understood, it has been 
hypothesised that observed differences could be related to sex hormones (i.e. oestrogen) [14], 
as there is evidence that oestrogen can influence serotonin system function [9, 32]. 
Furthermore, female mice exposed to prenatal maternal stress display significantly higher 
basal and stress-induced plasma corticosterone concentrations as well as reductions in the 
density of hippocampal glucocorticoid receptors, compared to non-stressed controls [33-35]. 
These sex-specific differences may be associated with reductions in placental 11β-
hydroxysteroid dehydrogenase type 2 (11β-HSD2) activity, which has been associated with 
reduced fetal growth and higher cortisol concentrations in the umbilical vein of female, but 
not male, infants of mothers with untreated asthma [36]. It is important to note that the risks 
associated with exposures during fetal life may be modulated by the postnatal environment. 
This effect may also be sex-specific, with quality of maternal care in the early postnatal 
period shown to influence hippocampal volume in adulthood in females, but not males [37].   
Few studies have investigated long-term growth outcomes amongst children exposed 
to SSRIs or antidepressants in utero [17-19], especially beyond 12 months of age. This study 
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has a number of strengths compared to our previous study involving just 71 exposed children 
[38], which identified an association between prenatal SSRI exposure and a decreased risk of 
overweight among female (aPR 0.23 [0.05, 0.98]), but not male (aPR 1.17 [0.54, 2.51]), 
children at 4- to 5-years of age. The current study included more detailed data on the use of 
SSRIs and other psychotropic medications during pregnancy and more detailed assessment of 
potentially confounding maternal and infant covariates including prenatal stress score, weight 
gain during pregnancy, paternal BMI and duration of breastfeeding.  
While male children with prenatal SSRI exposure were at increased risk of being 
overweight at 7- years of age, this was not supported by a corresponding increase in BMI-z 
score (0.3 [-0.06, 0.66]). This apparent incongruence reflects challenges associated with 
utilising standardised cut-points as opposed to continuous measures to evaluate outcomes and 
may reflect an alteration in the distribution of BMI-z scores among the male children with 
prenatal SSRI exposure.  
A major strength of this study is inclusion of women with untreated psychiatric 
illness. In addition to the effects on the serotonergic system, exposure to maternal stress 
during gestation has been demonstrated to adversely affect development and regulation of the 
HPA axis [39, 40]. Maternal stress during pregnancy increases circulating concentrations of 
glucocorticoids, which can enter the fetal circulation and down-regulate central 
glucocorticoid receptors in the hippocampus. This leads to reduced feedback inhibition and 
an overactive HPA axis, resulting in increased cortisol secretion in the basal state and in 
conditions of stress [41, 42]. This has a number of important implications for metabolic 
function in later life, as overactivity of the HPA axis has been associated with a range of 
cardio-metabolic outcomes in later life, including hypertension, insulin resistance and obesity 
[43, 44]. 
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Notably, a recent study demonstrated an association between prenatal stress (related 
to maternal bereavement immediately prior to pregnancy) and increased risk of childhood 
overweight [20]. Importantly, the increased risk of overweight was only observed in children 
beyond 10 years of age. That study did not include stratification of data by sex, and it was not 
clear how many women, if any, were taking SSRIs during pregnancy.  
In light of this, we observed an association between psychiatric illness during 
pregnancy and increased risk of overweight in female children at 7-years of age (aPR 1.45 
[1.05, 2.02]). While this finding was in accordance with evidence obtained from animal 
studies [16], it contrasts the recent finding of Ingstrup et al.[45] who, also using data from the 
DNBC, observed a small tendency of overweight in males (aOR 1.15 [0.99, 1.33]) but not 
females (aOR 0.98 [0.85, 1.13]) at 7-years of age who were exposed to maternal distress 
during pregnancy. The contrasting results could be explained by a number of key 
methodological differences in that we included a separate group of women who were taking a 
SSRI during pregnancy and excluded women exposed to psychotropic medication other than 
SSRIs. Furthermore, we classified childhood overweight as a BMI at or exceeding the age- 
and sex-specific 85th percentile, compared to a cut-off of >95th percentile [45].  
While the small number of infants exposed to SSRIs during pregnancy represents a 
study limitation, this is reflective of the low prevalence of SSRI use in Denmark in the study 
period [46]. Further limitations include the potential for selection bias as a result of 
incomplete data or loss to follow-up. However, when we compared incomplete data from 
partial responders with estimates from the main analysis based on complete data we observed 
no differences in the prevalence of childhood overweight. Furthermore, to assess the impact 
of loss to follow-up, we attached inverse probability weighting to subjects included in the 
analyses to restore the representation of those lost to follow-up. This aims to construct a 
pseudo-population of the same size as the original study population, but in which nobody is 
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lost to follow-up [29]. We found no difference between the weighted and non-weighted 
results (data not presented).  
It is possible that some women did not accurately report taking a SSRI during 
pregnancy or having a psychiatric illness. However, since data on medication use and the 
presence of a psychiatric illness were collected prospectively, any exposure misclassification 
would most likely lead to a bias towards the null. Similarly, a degree of measurement error in 
relation to child heights and weights is expected, but unlikely related to maternal exposure. 
This is supported by a validation study in 1200 children participating in the 7-year follow-up, 
which found no systematic errors in maternal self-reported child heights and weights [47]. 
Although the inclusion of a control group of women with untreated psychiatric illness 
accounted for confounding by the indication for treatment to some extent, residual 
confounding due to the type or severity of the underlying maternal psychiatric illness might 
still prevail. Differences in outcomes according to types of psychiatric illnesses reported by 
women (e.g. depression, anxiety) were not evaluated. The presence of maternal psychiatric 
illness during early phases of childhood development may result in suboptimal nutritional 
intake among these children. This may occur through negative effects on mother–child 
interactions or differences in feeding practices [48]. Conversely, women with psychiatric 
illness may have more obesogenic behaviours (i.e. abnormal eating behaviours or physical 
activity levels), which are passed on to their children. We had no data on paternal psychiatric 
illness which could also play an important role in influencing childhood outcomes. 
The lack of inclusion of data on postnatal factors such as the child’s diet, energy 
intake and physical activity may constitute a study limitation. However, these factors lie in 
the predicted pathway between prenatal SSRI exposure and childhood overweight, given the 
involvement of the serotonergic system in the regulation of appetite (influencing energy 
intake[6-8]) as well as motor control (influencing physical activity in later life[49]).  
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We observed the potential for opposing sex-specific differences in the long-term 
effects of prenatal exposure to SSRI use and/or maternal psychiatric illness on childhood 
overweight. Limitations of the present study, including the small number of children exposed 
to SSRIs and maternal psychiatric illness, suggest further research in this area may be 
warranted with larger sample sizes and longer follow-up. It is also important for future 
research to examine other potential long-term effects associated with prenatal exposure to 
SSRI use and/or maternal psychiatric illness and the role of child sex on those outcomes. 
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Table 1. Demographic and Clinical Measures for Women and Children Exposed to a SSRI Antidepressant, Psychiatric Illness Without 
SSRIs, or Neither During Pregnancy. 










P for SSRI vs 
Unexposed 
      
Maternal Age,  
     mean (SD), years 
30.7 (4.3) 29.9 (4.7) 0.096 30.2 (4.2) 0.203 
Maternal BMI, n (%)†      
<25 kg/m2 91 (71.7) 332 (68.5) 0.333 26 016 (73.6) 0.300 
≥25 & <30 kg/m2 22 (17.3) 111 (22.9)  6 719 (19.0)  
≥30 kg/m2 14 (11.0) 42 (8.7)  2 636 (7.5)  
Paternal BMI, n (%)†      
<25 kg/m2 73 (60.3) 239 (52.8) 0.091 18 410 (53.3) 0.255 
≥25 & <30 kg/m2 39 (32.2) 169 (37.3)  13 643 (39.5)  
≥30 kg/m2 9 (7.4) 45 (9.9)  2 522 (7.3)  
Weight Gain During Pregnancy, n 
(%)† 
     
Low 25 (19.8) 88 (18.5) 0.517 5 788 (16.5) 0.117 
Normal 37 (29.4) 166 (34.8)  13 416 (38.2)  
High 64 (50.8) 223 (46.8)  15 880 (45.3)  
Parity      
≥1, n (%)† 68 (53.5) 284 (58.0) 0.669 19 121 (53.8) 0.951 
Socioeconomic Status, n (%)†      
High 84 (66.7) 270 (55.6) 0.033 24 822 (70.0) 0.001 
Middle 31 (24.6) 180 (37.0)  9 617 (27.1)  
Low 11 (8.7) 36 (7.4)  1 034 (2.9)  
Smoking Status, n (%)†      
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Non Smoker 76 (59.8) 340 (69.4) 0.068 28 690 (80.7) <0.001 
1-10 cigarettes per day 37 (29.1) 97 (19.8)  5 146 (14.5)  
>11 cigarettes per day 14 (11.0) 53 (10.8)  1 730 (4.9)  
Breastfeeding, n (%)†   0.884  0.085 
< 1 month 10 (7.9) 46 (9.4)  1 890 (5.3)  
1-4 months 26 (20.5) 91 (18.6)  4 245 (11.9)  
≥4 months 91 (71.7) 353 (72.0)  29 403 (82.7)  
Prenatal Distress Score,   mean (SD) 5.1 (3.7) 7.0 (4.0) <0.001 2.6 (2.4) <0.001 
Postnatal Distress Score,     mean (SD) 4.5 (3.9) 5.1 (4.0) 0.129 2.1 (2.6) <0.001 
      
Child Sex      
Male, n (%)† 64 (50.4) 251 (51.2) 0.867 18 248 (51.3) 0.838 
Birth Weight,  
     mean (SD), years 
     
Male 3 697 (557) 3 640 (612) 0.595 3 683 (547) 0.877 
Female 3 462 (656) 3 465 (569) 0.588 3 557 (526) 0.527 
Gestational Age, mean (SD), weeks      
Male 39.7 (1.5) 39.9 (1.6) 0.359 40.0 (1.6) 0.060 
Female 39.9 (1.7) 39.9 (1.6) 0.935 40.1 (1.5) 0.215 
Age of Child at Measurement, mean 
(SD), months 
84.5 (3.2) 84.5 (3.4) 0.979 84.5 (3.4) 0.847 
Childhood Overweight (BMI>85th 
Percentile), n (%)† 
     
Male 16 (25.0) 39 (15.5) 0.075 2 305 (12.6) 0.003 
Female 8 (12.7) 38 (15.9) 0.750 1 978 (11.4) 0.750 
Childhood BMI-z Score, mean (SD)      
Male 0.16 (1.0) -0.05 (1.2) 0.192 -0.08 (1.0) 0.065 
Female -0.13 (1.1) 0.06 (1.0) 0.181 -0.09 (1.2) 0.794 
† Percentages are calculated from available (non-missing) data. 
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Table 2. Risk of overweight at 7-years of age for children of women exposed to SSRI 
Antidepressants, Psychiatric Illness Without SSRIs, or Neither During Pregnancy 
  
Maternal SSRI Use 
vs. Psychiatric 
Illness 


















1.12 [0.71, 1.77] 1.39 [0.94, 2.05] 1.24 [0.98, 1.56] 












1.78 [1.01, 3.12] 1.54 [1.01, 2.37] 1.06 [0.76, 1.50] 












0.86 [0.37, 1.99] 0.99 [0.43, 2.26] 1.45 [1.05, 2.02] 
 
Model 1. PR adjusted for maternal age, smoking status, pre-existing diabetes, gestational diabetes, 
pre-pregnancy maternal BMI, socioeconomic status, prenatal distress and paternal BMI  
Model 2. PR adjusted as in Model 1 and also for neonatal birth weight, weight gain during pregnancy, 
breastfeeding and postnatal distress  
 
Author’s Post-Print Version; Copyright – Ann Epidemiol; doi: 10.1016/j.annepidem.2013.08.005 
25 
 
Table 3. Linear regression coefficients for BMI-z score at 7-years of age for children of 
women exposed to SSRI Antidepressants, Psychiatric Illness Without SSRIs, or Neither 
During Pregnancy  
  
Maternal SSRI Use 
vs. Psychiatric 
Illness 




















0.04 [-0.19, 0.26] 0.10 (-0.09, 0.29] 0.06 [-0.05, 0.18] 












0.30 [-0.06, 0.66] 0.11 [-0.17, 0.39] -0.07 [-0.24, 0.11] 












-0.10 [-0.39, 0.20] 0.07 [-0.18, 0.31] 0.21 [0.06, 0.36] 
 
Model 1. PR adjusted for maternal age, smoking status, pre-existing diabetes, gestational diabetes, 
pre-pregnancy maternal BMI, socioeconomic status, prenatal distress and paternal BMI  
Model 2. PR adjusted as in Model 1 and also for neonatal birth weight, weight gain during pregnancy, 
breastfeeding and postnatal distress  
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Supplementary Table 1. Demographic and Clinical Measures for Women and Children 
Who Were Lost and Not Lost to Follow-Up  
 







Maternal Age,  
     mean (SD), years 
29.8 (4.3) 30.2 (4.2) 0.000 
Maternal BMI, n (%)†    
<25 kg/m2 29 088 (70.4) 26 439 (73.4) 0.000 
≥25 & <30 kg/m2 8 410 (20.3) 6 852 (19.0)  
≥30 kg/m2 3 848 (9.3) 2 692 (7.5)  
Paternal BMI, n (%)†    
<25 kg/m2 18 684 (52.8) 18 722 (53.3) 0.410 
≥25 & <30 kg/m2 14 113 (39.9) 13 851 (39.4)  
≥30 kg/m2 2 612 (7.4) 2 576 (7.3)  
Weight Gain During 
Pregnancy, n (%)† 
   
Low 5 067 (16.8) 5 901 (16.5) 0.000 
Normal 10 599 (35.2) 13 619 (38.2)  
High 14 434 (48.0) 16 167 (45.3)  
Parity    
≥1, n (%)† 24 597 (56.4) 19 473 (53.8) 0.000 
Socioeconomic Status, n 
(%)† 
   
High 27 139 (65.4) 25 176 (69.8) 0.000 
Middle 12 577 (30.3) 9 828 (27.2)  
Low 1 758 (4.2) 1 081 (3.0)  
Smoking Status, n (%)†    
Non Smoker 31 461 (75.5) 29 106 (80.4) 0.000 
1-10 cigarettes per day 7 464 (17.9) 5 280 (14.6)  
>11 cigarettes per day 2 733 (6.6) 1 797 (5.0)  
Breastfeeding, n (%)†    
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< 1 month 2 390 (7.2) 1 946 (5.4) 0.000 
1-4 months 5 192 (15.6) 4 362 (12.1)  
≥4 months 25 815 (77.3) 29 847 (82.6)  
Prenatal Distress Score,   
mean (SD) 
2.9 (2.7) 2.6 (2.5) 0.000 
Postnatal Distress Score,     
mean (SD) 
2.3 (2.9) 2.2 (2.7) 0.000 
Exposure Status    
Unexposed 42 585 (97.6) 35 568 (98.3) 0.000 
Psychiatric Illness 781 (1.8) 490 (1.4)  
SSRI Use 249 (0.6) 127 (0.4)  
Child Sex    
Male, n (%)† 22 242 (51.0) 18 563 (51.3) 0.393 
Birth Weight,  
     mean (SD), years 
3 569 (584) 3 621 (541) 0.000 
Gestational Age, mean 
(SD), weeks 
39.9 (2.3) 40.1 (2.1) 0.000 
† Percentages are calculated from available (non-missing) data. 
